Inhibitex to Present at the Jefferies 2011 Global Healthcare Conference

ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell Plumb, president and chief executive officer, will present an overview of the Company and an update of its pipeline of differentiated anti-infective compounds at the Jefferies 2011 Global Healthcare Conference on June 6, 2011 at 8:00 AM (EDT). The conference is being held at the Grand Hyatt Hotel in New York City.

About Inhibitex

Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase II for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.



CONTACT:

Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, 646-378-2922
[email protected]

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.